This is the third and final part of our discussion on the South Asian gut, part 1 and part 2 here. From here we will move on to the liver next week.
Feedback on topics always welcome!
At Zinda, we don’t care about the hype. We care about the phenotype.
Nothing has garnered hype like GLP-1. Super bowl level hype.
For the South Asian community however, GLP-1s may be the most important medication, almost a miracle. It’s not just about fitting into a wedding outfit; it’s about correcting a fundamental evolutionary mismatch.
Lets get into it.
In our previous deep dives, we’ve explored the “Thin-Fat” Paradox, how South Asians suffer from metabolic disease at lower body weights than our Western counterparts. We’ve discussed our “Thrifty Genotype”, an evolutionary adaptation for starvation that has become a liability in the age of abundance. And over the last month delved into the South Asian gut, how its lining, microbiota and axis form a circuit incongruous to a diaspora.
Today, we are connecting those dots, all seemingly leading toward GLP-1s and why they could be metabolic correctors ideal for the specific bottlenecks in the South Asian phenotype.
GLP-1s 101
Before we dive into the South Asian specifics, let’s strip away the brand names and look at the molecule fundamentally.
GLP-1 (aka Glucagon-like Peptide-1) is an incretin hormone naturally produced in your gut after you eat. Like most peptides, they are signaling molecules, messengers who instruct the target cell/organ to do something. In the case of GLP-1s, it communicates between the gut and the rest of the body.
When you eat a meal, GLP-1 travels through your system to coordinate a complex physiological response:
In The Brain: It binds to receptors in the hypothalamus to shut down “food noise” that constant mental chatter asking “What’s for dinner?” while you’re eating lunch.
In The Stomach: It slows gastric emptying, keeping you physically fuller for longer.
In The Pancreas: It primes the beta-cells to release insulin, but crucially only when glucose is elevated. This “glucose-dependent” mechanism is why it rarely causes dangerous lows (aka hypoglycemia), unlike older drugs (though risks increase if combined with insulin or sulfonylureas).
In The Liver: It suppresses glucagon secretion from pancreatic alpha cells, thereby stopping your liver from dumping stored sugar into your bloodstream unnecessarily.
For many people, this reads like weight loss. For South Asians, it can function more like metabolic triage, because the bottleneck is earlier, and the margin for error is smaller.
Resistance, Not Deficiency
When we talk about metabolic health, we obsess over insulin. We track spikes, we fear resistance, and we measure fasting levels. But insulin is just the soldier; it follows orders. We are slowly learning the real commanders are the incretins, hormones like GLP-1 that dictate how your body handles a meal.
Now, you might assume that because South Asians get diabetes earlier and more aggressively, we simply lack these hormones. The reality is the exact opposite.
Research comparing healthy young South Asians to Caucasians found a fascinating paradox: in response to sugar, South Asians actually secrete significantly higher levels of GLP-1.
Why?
Think of it as a scream for help. Your body “senses” the metabolic struggle, the insulin resistance in your liver and muscles, and the gut pumps out extra GLP-1 to force the pancreas to respond. But just like we are insulin resistant, we appear to be GLP-1 resistant.
Research strongly supports a “Compensatory Scream” hypothesis. Sleddering et al. (2014) found that healthy young South Asians secreted ~45% more GLP-1 (AUC) than matched Caucasians during a glucose challenge, yet still exhibited higher insulin resistance. This appears specific to our phenotype; Chong et al. (2022) showed that Indians produce significantly more GLP-1 than Chinese or Malays, directly correlating with metabolic dysfunction. Essentially, while the gut is working overtime to stimulate insulin (Misra, 2020), it is fighting a losing battle against systemic defects.
The signal is loud, but the body isn’t listening, a mismatch that suggests a distinct form of “GLP-1 resistance.”